Update on hepatitis C virus-specific immunity

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 559-565

  Ciuffreda, Donatella ^a   Kim, Arthur Y ^b  

^a Gastrointestinal Unit   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CD4 T cell; CD8 T cell; HLA; inhibitory markers

Indexed keywords

INTERLEUKIN 28B;

APOPTOSIS; BACTERIAL TRANSLOCATION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; DISEASE COURSE; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION CONTROL; LIVER FIBROSIS; MIXED INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS LOAD;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HLA ANTIGENS; HUMANS;

EID: 80054910166     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834b879e     Document Type: Review

References (103)

1. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-1754.
2. Kim AY, Chung RT. Coinfection with HIv-1 and HCv: a one-two punch. Gastroenterology 2009; 137:795-814.
3. Vtakaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a singlesource outbreak of hepatitis C. Nature Med. 2000, 6, 578-582. (Pubitemid 30305910)
4. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005; 42:104-112. (Pubitemid 40911317)
5. Grakoui A, Shoukry NH, Woollard DJ, et al. HCv persistence and immune evasion in the absence of memory T cell help. Science 2003; 302:659-662. (Pubitemid 37310924)
6. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197:1645-1655. (Pubitemid 36745340)
7. + T cells in HIv-infected progressors and long-term nonprogressors. J Immunol 2000; 165:1082-1092. (Pubitemid 30484780)
8. Draenert R, verrill CL, Tang Y, et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J virol 2004; 78:630-641. (Pubitemid 38067584)
9. Lauer GM, Nguyen TN, Day CL, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J virol 2002; 76:2817-2826. (Pubitemid 34184868)
10. + T-cell count in individuals coinfected with HIv-1. Blood 2005; 105:1170-1178. (Pubitemid 40170890)
11. Dutoit v, Ciuffreda D, Comte D, et al. Differences in HCv-specific T cell responses between chronic HCv infection and HIv/HCv co-infection. Eur J Immunol 2005; 35:3493-3504. (Pubitemid 43025531)
12. Ciuffreda D, Comte D, Cavassini M, et al. Polyfunctional HCv-specific T-cell responses are associated with effective control of HCv replication. Eur J Immunol 2008; 38:2665-2677.
13. Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virusspecific T cell responses and recurrent hepatitis C virus in HIv coinfection. PLoS Med 2006; 3:e492.
14. Rohrbach J, Robinson N, Harcourt G, et al. Cellular immune responses to HCv core increase and HCv RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59:1252-1258.
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
16. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
17. Suppiah v, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
18. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
19. Thio CL, Gao X, Goedert JJ, et al. HLA-Cw*04 and hepatitis C virus persistence. J virol 2002; 76:4792-4797.
20. McKiernan SM, Hagan R, Curry M, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40:108-114. (Pubitemid 38877575)
21. Kuniholm MH, Kovacs A, Gao X, et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 2010; 51:1514-1522.
22. Kim AY, Kuntzen T, Timm J, et al. Spontaneous control of HCv is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011; 140:686-96e1.
23. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIv infection in the absence of therapy. J Infect Dis 2008; 197:563-571. (Pubitemid 351321534)
24. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIv-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
25. + T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J virol 2009; 83:2728-2742.
26. Ruiz-Mateos E, Machmach K, Romero-Sanchez MC, et al. Hepatitis C virus replication in Caucasian HIv controllers. J viral Hepat 2011; 18:e350-e357.
27. Timm J, Lauer GM, Kavanagh DG, et al. CD8 epitope escape and reversion in acute HCv infection. J Exp Med 2004; 200:1593-1604. (Pubitemid 40094183)
28. Tester I, Smyk-Pearson S, Wang P, et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 2005; 201:1725-1731. (Pubitemid 41002891)
29. Cox AL, Mosbruger T, Mao Q, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005; 201:1741-1752. (Pubitemid 41002893)
30. Kuntzen T, Timm J, Berical A, et al. viral sequence evolution in acute hepatitis C virus infection. J virol 2007; 81:11658-11668. (Pubitemid 47623798)
31. Gaudieri S, Rauch A, Park LP, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J virol 2006; 80:11094-11104. (Pubitemid 44706550)
32. TimmJ, Li B, Daniels MG, et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 2007; 46:339-349. (Pubitemid 47344768)
33. Lange CM, Roomp K, Dragan A, et al. HLA class I allele associations with HCv genetic variants in patients with chronic HCv genotypes 1a or 1b infection. J Hepatol 2010; 53:1022-1028.
34. + T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology 2011; 140:2064-2073.
35. Fitzmaurice K, Petrovic D, Ramamurthy N, et al. Molecular footprints reveal the impact of the protective HLA-A*0vallele in hepatitis C virus infection. Gut 2011. [Epub ahead of print]
36. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009; 49:1069-1082.
37. Salloum S, Kluge SF, Kim AY, et al. The resistance mutation R155K in the NS3/4A protease of hepatitis C virus also leads the virus to escape from HLA-A*68-restricted CD8 T cells. Antiviral Res 2010; 87:272-275.
38. + T cells limit HCv escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009; 119: 376-386.
39. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIv-1 to human leukocyte antigen class I. Nature 2009; 458:641-645.
40. + T-cell epitope. Hepatology 2010; 51:54-62.
41. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009; 10: 1819-1837.
42. + T-cell responses during chronic hepatitis C virus infection. J Gen virol 2010; 91 (Pt 6):1396-1406.
43. Fuller MJ, Shoukry NH, Gushima T, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010; 51:378-387.
44. Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in HIv-1 infected individuals. J Gen virol 2011. [Epub ahead of print]
45. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-793. (Pubitemid 26372655)
46. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009; 229:271-293.
47. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-3895.
48. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-413.
49. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4: 670-679. (Pubitemid 36874444)
50. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-687. (Pubitemid 43237609)
51. + T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-684. (Pubitemid 47615511)
52. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10:29-37.
53. + T cells upon acute versus persistent viral infection. Immunity 1998; 9:449-457. (Pubitemid 28499196)
54. + T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J virol 2003; 77:10900-10909. (Pubitemid 37204283)
55. Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest 2006; 116:1675-1685.
56. Brooks DG, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J virol 2005; 79:10514-10527. (Pubitemid 41098591)
57. Sester U, Presser D, Dirks J, et al. PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8:1486-1497. (Pubitemid 351989503)
58. + T cells. J virol 2009; 83:9122-9130.
59. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIv-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006; 203:2223-2227. (Pubitemid 44498355)
60. Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011; 186:4200-4212.
61. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIv-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354. (Pubitemid 44435155)
62. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8:1246-1254. (Pubitemid 350011764)
63. + T cells during acute HCv infection, irrespective of clinical outcome. J virol 2008; 82:3154-3160. (Pubitemid 351329205)
64. Nakamoto N, Kaplan DE, Coleclough J, et al. Functional restoration of HCvspecific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008; 134:1927-1937; 37 e1-2.
65. + T cell survival in HIv infection. J Exp Med 2006; 203: 2281-2292. (Pubitemid 44498363)
66. + T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202. (Pubitemid 44527357)
67. Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J virol 2007; 81:2545-2553. (Pubitemid 46447020)
68. Boni C, Fisicaro P, valdatta C, et al. Characterization of hepatitis B virus (HBv)-specific T-cell dysfunction in chronic HBv infection. J virol 2007; 81:4215-4225. (Pubitemid 46586915)
69. + T cells in patients with chronic infection. Gastroenterology 2011. [Epub ahead of print]
70. Garni-Wagner BA, Purohit A, Mathew PA, et al. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol 1993; 151:60-70. (Pubitemid 23206971)
71. Trinchieri G, valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993; 12:218-234. (Pubitemid 23297441)
72. Schuhmachers G, Ariizumi K, Mathew PA, et al. Activation of murine epidermal gamma delta T cells through surface 2B4. Eur J Immunol 1995; 25:1117-1120.
73. Nakajima H, Cella M, Langen H, et al. Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur J Immunol 1999; 29:1676-1683. (Pubitemid 29224473)
74. + effector alpha beta T cells. J Immunol 2001; 167:6165-6170. (Pubitemid 33081543)
75. + T-cell function. Hepatology 2010; 52:1934-1947.
76. + T cells in HIv-1-infected patients with progressing disease. J Immunol 1999; 162:7563-7568. (Pubitemid 29277738)
77. + T-cell exhaustion in HIv infection. Blood 2011; 117:4805-4815.
78. +T cells. PLoS Pathog 2011; 7:e1002045.
79. Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990; 171:1393-1405. (Pubitemid 20167538)
80. Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 1992; 176:327-337.
81. Huard B, Mastrangeli R, Prigent P, et al. Characterization of the major histocompatibility complex class II binding site on LAG-vprotein. Proc Natl Acad Sci U S A 1997; 94:5744-5749. (Pubitemid 27241841)
82. Huang CT, Workman CJ, Flies D, et al. Role of LAG-vin regulatory T cells. Immunity 2004; 21:503-513.
83. Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene v(LAG-3) on B cells is induced by T cells. Eur J Immunol 2005; 35:2081-2088. (Pubitemid 41015047)
84. Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-vmolecules inhibit CD3/TCR signaling. J Immunol 1998; 161:4058-4065. (Pubitemid 28468984)
85. Rotger M, Dalmau J, Rauch A, et al. Comparative transcriptomics of extreme phenotypes of human HIv-1 infection and SIv infection in sooty mangabey and rhesus macaque. J Clin Invest 2011; 121:2391-2400.
86. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010; 6:e1000947.
87. Maiza H, Leca G, Mansur IG, et al. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 1993; 178:1121-1126. (Pubitemid 23260453)
88. Bensussan A, Gluckman E, el Marsafy S, et al. BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. Proc Natl Acad Sci U S A 1994; 91:9136-9140.
89. Anumanthan A, Bensussan A, Boumsell L, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 1998; 161:2780-2790. (Pubitemid 28425697)
90. Maeda M, Carpenito C, Russell RC, et al. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. J Immunol 2005; 175:4426-4432. (Pubitemid 41361978)
91. + T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008; 9:176-185.
92. Adams AB, Larsen CP, Pearson TC, Newell KA. The role of TNF receptor and TNF superfamily molecules in organ transplantation. Am J Transplant 2002; 2:12-18. (Pubitemid 36306802)
93. Porichis F, Kwon DS, Zupkosky J, et al. Responsiveness of HIv-specific CD4 T cells to PD-1 blockade. Blood 2011; 118:965-974.
94. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-vregulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415:536-541. (Pubitemid 34130609)
95. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-vexpression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIv-1 infection. J Exp Med 2008; 205:2763-2779.
96. vali B, Jones RB, Sakhdari A, et al. HCv-specific T cells in HCv/HIv co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with Liver disease progression. Eur J Immunol 2010; 40:2493-2505.
97. McMahan RH, Golden-Mason L, Nishimura MI, et al. Tim-vexpression on PD- 1+ HCv-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120:4546-4557.
98. Keir ME, Sharpe AH. The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005; 204:128-143. (Pubitemid 40460498)
99. + T cells in acute infection is linked to sufficient IL-2 signaling. J Immunol 2010; 184:2410-2422.
100. Rallon NI, Barreiro P, Soriano v, et al. Elevated TGF-beta1 levels might protect HCv/HIv-coinfected patients from Liver fibrosis. Eur J Clin Invest 2011; 41:70-76.
101. Sturm N, Thelu MA, Camous X, et al. Characterization and role of intrahepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol 2010; 53:25-35.
102. Flynn JK, Dore GJ, Hellard M, et al. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J viral Hepat 2011; 18:549-561.
103. O'Garra A, vieira P. TH1 cells control themselves by producing interleukin- 10. Nat Rev Immunol 2007; 7:425-428. (Pubitemid 46834852)